Key Points
- Musa Tariq sold 348 shares of Guardant Health on March 18 at an average price of $88.09 for about $30,655, reducing his holdings to 8,394 shares (a 3.98% decrease).
- Shares traded down 2.8% to $86.57 with 101,765 shares changing hands; the stock has a market cap of $11.36 billion, a 52‑week range of $36.36–$120.74, and a negative P/E of -26.31.
- Guardant beat revenue estimates with $281.3M but missed EPS at ($0.50) versus ($0.43) expected, while analysts remain largely positive with a consensus rating of "Moderate Buy" and an average target of $122.57.
Guardant Health, Inc. (NASDAQ:GH - Get Free Report) Director Musa Tariq sold 348 shares of the firm's stock in a transaction dated Wednesday, March 18th. The stock was sold at an average price of $88.09, for a total value of $30,655.32. Following the completion of the sale, the director directly owned 8,394 shares in the company, valued at approximately $739,427.46. The trade was a 3.98% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.
Guardant Health Trading Down 2.8%
Shares of NASDAQ GH traded down $2.51 on Friday, reaching $86.57. 101,765 shares of the company traded hands, compared to its average volume of 1,975,577. Guardant Health, Inc. has a fifty-two week low of $36.36 and a fifty-two week high of $120.74. The company has a 50 day moving average of $102.31 and a 200 day moving average of $90.30. The stock has a market capitalization of $11.36 billion, a PE ratio of -26.31 and a beta of 1.67.
Guardant Health (NASDAQ:GH - Get Free Report) last released its earnings results on Thursday, February 19th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.07). The company had revenue of $281.27 million for the quarter, compared to analyst estimates of $269.74 million. During the same quarter in the previous year, the company earned ($0.62) earnings per share. The business's revenue was up 39.4% on a year-over-year basis. As a group, research analysts expect that Guardant Health, Inc. will post -2.9 earnings per share for the current year.
Analyst Ratings Changes
A number of brokerages recently weighed in on GH. Robert W. Baird initiated coverage on Guardant Health in a report on Tuesday, February 17th. They issued an "outperform" rating and a $120.00 target price on the stock. JPMorgan Chase & Co. raised their price objective on Guardant Health from $120.00 to $130.00 and gave the stock an "overweight" rating in a report on Friday, February 20th. Morgan Stanley lifted their price objective on Guardant Health from $105.00 to $130.00 and gave the company an "overweight" rating in a research note on Monday, December 1st. Barclays reissued an "overweight" rating and set a $130.00 target price on shares of Guardant Health in a research report on Friday, February 20th. Finally, Stifel Nicolaus raised their price target on shares of Guardant Health from $120.00 to $130.00 and gave the company a "buy" rating in a report on Friday, February 20th. Twenty-one research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Guardant Health presently has an average rating of "Moderate Buy" and a consensus target price of $122.57.
Get Our Latest Research Report on GH
Institutional Investors Weigh In On Guardant Health
Several institutional investors and hedge funds have recently modified their holdings of GH. V Square Quantitative Management LLC purchased a new stake in shares of Guardant Health during the 4th quarter valued at about $27,000. Chesapeake Asset Management LLC acquired a new stake in Guardant Health in the fourth quarter valued at approximately $28,000. Thurston Springer Miller Herd & Titak Inc. purchased a new stake in shares of Guardant Health during the fourth quarter valued at approximately $31,000. Elyxium Wealth LLC acquired a new position in shares of Guardant Health during the fourth quarter worth $35,000. Finally, Parallel Advisors LLC lifted its position in shares of Guardant Health by 164.7% during the fourth quarter. Parallel Advisors LLC now owns 352 shares of the company's stock worth $36,000 after purchasing an additional 219 shares in the last quarter. Hedge funds and other institutional investors own 92.60% of the company's stock.
About Guardant Health
(
Get Free Report)
Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health's mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.
The company's flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
